Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV-COMPARE
ISRCTN79815558Phase 3Completed
- Sponsor
- Valneva
- Start
- Apr 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of VLA2001 and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Valneva. Primary endpoints: Neutralizing antibody geometric mean titer on Day 43 and Adverse events through Day 43. Started Apr 2021; status: completed.
02
Drugs
VLA2001ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN79815558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79815558.